DESTINY-Breast05 Explained: Can We Beat T-DM1?

For patients with residual disease, DESTINY-Breast05 asked a critical question — and delivered a decisive answer.

This clip breaks down how T-DXd outperformed T-DM1 in invasive disease-free survival, what that means for curative intent therapy, and why this data may soon redefine the adjuvant standard of care.